What is HC Wainwright's Forecast for EBS Q1 Earnings?

Emergent BioSolutions Inc. (NYSE:EBS - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for Emergent BioSolutions in a report released on Tuesday, March 4th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.40. The firm had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the prior year, the company posted ($0.77) EPS.

Separately, StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Remove Ads

Emergent BioSolutions Trading Down 2.0 %

EBS traded down $0.12 during midday trading on Thursday, hitting $5.66. 1,406,287 shares of the company were exchanged, compared to its average volume of 2,642,277. The firm's 50 day moving average price is $9.33 and its 200-day moving average price is $8.94. Emergent BioSolutions has a 1-year low of $1.82 and a 1-year high of $15.10. The firm has a market capitalization of $307.28 million, a P/E ratio of -1.38 and a beta of 1.80. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently bought and sold shares of the company. Aegis Wealth Management LLC acquired a new position in shares of Emergent BioSolutions in the 4th quarter valued at about $145,000. B. Riley Wealth Advisors Inc. lifted its stake in Emergent BioSolutions by 21.9% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 41,800 shares of the biopharmaceutical company's stock valued at $400,000 after buying an additional 7,500 shares during the period. Alpine Global Management LLC bought a new position in shares of Emergent BioSolutions during the 4th quarter worth approximately $112,000. Two Sigma Advisers LP boosted its holdings in shares of Emergent BioSolutions by 14.1% during the 4th quarter. Two Sigma Advisers LP now owns 656,500 shares of the biopharmaceutical company's stock worth $6,276,000 after buying an additional 81,000 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Emergent BioSolutions by 13.9% during the 4th quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company's stock worth $8,095,000 after buying an additional 103,574 shares during the period. Institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.